It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
After 4 years of research funded by Israel’s Ministry of Science & Technology, MIGAL’s researchers have developed an effective vaccine against avian coronavirus Infectious Bronchitis Virus (IBV), to be adapted soon and create a human vaccine against COVID-19.
David Zigdon, CEO of MIGAL GALILEE RESEARCH INSTITUTE, said, “Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development. Our goal is to produce the vaccine during the next 8-10 weeks, and to achieve safety approval in 90 days. This will be an oral vaccine, making it particularly accessible to the general public. We are currently in intensive discussions with potential partners that can help accelerate the in-human trials phase and expedite the completion final product development and regulatory activities.”
Dr. Chen Katz, MIGAL’s Biotechnology Group Leader, commented, “The scientific framework for the vaccine is based on a new protein expression vector, which forms and secretes a chimeric soluble protein that delivers the viral antigen into mucosal tissues by self-activated endocytosis (a cellular process in which substances are brought into a cell by surrounding the material with cell membrane, forming a vesicle containing the ingested material), causing the body to form antibodies against the virus. In pre-clinical (IN-VIVO) trials, MIGAL’s researchers have demonstrated that the oral vaccination induces high levels of specific anti-IBV antibodies.